10.50p+0.25 (+2.44%)26 Feb 2024, 16:20
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Verici Dx PLC Fundamentals

Company NameVerici Dx PLCLast Updated2024-02-26
IndustryDiagnostics & ResearchSectorHealthcare
Shares in Issue242.541 mMarket Cap£25.47 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-$0.07EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0.0664Debt Equity Ratio0.0691
Asset Equity Ratio1.3985Cash Equity Ratio0.7848
Quick Ratio2.4453Current Ratio2.58
Price To Book Value4.8239ROCE0

Verici Dx PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Verici Dx PLC Company Financials

Assets20222021
Tangible Assets$2.01 m$786,000.00
Intangible Assets$1.97 m$2.01 m
Investments00
Total Fixed Assets$3.98 m$2.79 m
Stocks00
Debtors$177,000.00$250,000.00
Cash & Equivalents$9.80 m$10.34 m
Other Assets00
Total Assets$14.30 m$13.79 m
Liabilities20222021
Creditors within 1 year$2.25 m$1.80 m
Creditors after 1 year$544,000.000
Other Liabilities00
Total Liabilities$2.80 m$1.80 m
Net assets$11.51 m$11.98 m
Equity20222021
Called up share capital$219,000.00$182,000.00
Share Premium$32.95 m$20.35 m
Profit / Loss-$11.41 m-$8.33 m
Other Equity$11.51 m$11.98 m
Preference & Minorities00
Total Capital Employed$11.51 m$11.98 m
Ratios20222021
Debt Ratio$0.050
Debt-to-Equity$0.050
Assets / Equity1.39851.3985
Cash / Equity0.78480.7848
EPS-$0.07-$0.06
Cash Flow20222021
Cash from operating activities-$10.07 m-$6.34 m
Cashflow before financing$2.61 m-$6.41 m
Increase in Cash$1.30 m-$7.38 m
Income20222021
Turnover00
Cost of sales00
Gross Profit00
Operating Profit-$11.46 m-$8.33 m
Pre-Tax profit-$11.41 m-$8.33 m

Verici Dx PLC Company Background

SectorHealthcare
ActivitiesVerici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies which will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, that of the development of prognostic and diagnostic tests for kidney transplant patients.
Latest Interim Date29 Sep 2023
Latest Fiscal Year End Date5 Jun 2023

Verici Dx PLC Directors

AppointedNamePosition
2024-02-20Mr. Julian Huw Baines MBENon-Executive Director,Chairman
2023-06-05Sir Ian James Carruthers OBENon-Executive Director,Senior Independent Non-Executive Director
2023-06-05Mr. James Renwick McCulloughNon-Executive Director
2021-07-01Dr. Barbara MurphyNon-Executive Director
2022-05-25Ms. Sara Jane BarringtonExecutive Director,Chief Executive Officer
2022-12-07Dr. Lorenzo Giovanni GallonNon-Executive Director

Verici Dx PLC Contact Details

Company NameVerici Dx PLC
Address19 Stanwell Road, Avon House, Cardiff, CF64 2EZ
Telephone+44 2920710570
Websitehttps://www.vericidx.com

Verici Dx PLC Advisors